A shot of good cholesterol: Synthetic hdl, a new intervention for atherosclerosis

Journal of Cardiovascular Nursing

Volumn 19, Issue 6, 2004, Pages 421-424

  Dudley Brown, Sharon ^a  

^a CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

ApoA I Milano; Atherosclerosis; HDL

Indexed keywords

APOLIPOPROTEIN A1; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIOSCLEROSIS; BLOOD; DRUG EFFECT; GENETICS; HUMAN; HYPERLIPIDEMIA; ITALY; MUTATION; PHYSIOLOGY; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; HUMANS; HYPERLIPIDEMIAS; ITALY; MUTATION; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 16644381646     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200411000-00015     Document Type: Article

References (23)

1. American Heart Association. Cholesterol statistics. 2004. Available at:. Accessed March 8, 2004.
2. McDonald K. Lipid-lowering strategies. Adv Nurse Pract. December 2003;11:24-28.
3. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
4. Lauer MS, Fontanarosa, PB. Updated guidelines for cholesterol management. JAMA. 2001;285:2508-2509.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. National Cholesterol Education Program. ATP III Guidelines At-A-Glance Quick Desk Reference. 2001. Available at:. Accessed March 8, 2004.
7. Ballantyne CM, Hoogoveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003;146:227-233.
8. Sacks F. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol. 2002;90:139-143.
9. Colyar MR. Lipoprotein analysis. Adv Nurse Pract. May 2002;10:30-32.
10. Brousseau ME, Schaefer EJ. New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol. Curr Atheroscler Rep. 2001;3:365-372.
11. Wilson PWF. High-density lipoprotein, low-density lipoprotein and coronary heart disease. Am J Cardiol. 1990;66:7A-10A.
12. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary events in the Scandinavian Simvastatin Survival Study. Circulation. 1998;97:1453-1460.
13. Sacks FM, Tonkin AM, Shepherd J, et al, for the Prospective Pravastatin Pooling Project Investigators Group. The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation. 2000;102:1893-1900.
14. Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on treatment parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. Circulation. 2000;101: 477-484.
15. Srivastava R, Srivastava N. High-density lipoprotein, apolipoprotein A-I and coronary artery disease. Mol Cell Biochem. 2000;209:131-144.
16. Walldius G, Junger I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255:188-205.
17. Luc G, Bard J-M, Ferrieres J, et al, for the PRIME Study Group. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol. 2002;22:1155-1161.
18. von Eckardstein A, Fischer F, Schulte H, Tataru M-C, Kohler E, Assmann G. Association of serum apolipoprotein A-I (but not high-density lipoprotein cholesterol) with healed myocardial infarction in men independent of serum insulin and c-peptide. Am J Cardiol. 2001;88:723-726.
19. Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of HDL and apolipoprotein A-I increase by HMG CoA reductase inhibition in healthy subjects and patients with coronary artery disease. Atherosclerosis. 1999;144: 177-184.
20. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Circulation. 2001; 103:3047-3050.
21. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA. 2003;290: 2322-2324.
22. Cheisa G, Sirtori C. Recombinant apolipoprotein A-I Milano: a novel agent for the induction of regression of atherosclerotic plaques. Ann Med. 2003;35:267-273.
23. Barter P, Kastelein J, Nunn A, Hobbs R. High-density lipoproteins (HDLs) and atherosclerosis: the unanswered questions. Atherosclerosis. 2003;168:195-211.